1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

NICE Reform Plans Aim To Help Make Post-Brexit UK A ‘First-Launch’ Country

HTA Body's Methodology Review Includes Accepting More Uncertainty

 
• By Ian Schofield

Following a Brexit-induced delay over the summer, England's HTA body NICE has come up with a concrete set of proposals that it says will help it “robustly and efficiently” evaluate innovative technologies such as advanced therapies, histology-independent cancer treatments, and technologies for rare diseases. Industry bodies have welcomed the plans, which have just been put out for consultation.

Finger about to press a start button with the word innovation on the left. Composite between an image and a 3D background
NICE wants to ensure its ability to evaluate innovative technologies • Source: Shutterstock

NICE, the health technology assessment body for England, has launched its long-awaited consultation on changes to the methods it uses to assess new technologies such as medicines, medical products and diagnostics in a bid to ensure the methods “remain cutting edge and future proof.” 

Life science industry associations have welcomed the proposals, with one group saying the focus on removing significant barriers to access...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla

 
• By Neena Brizmohun

Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.

Lerodalcibep And First Generic Palbociclib Among 10 New EMA Filings

 
• By Neena Brizmohun

Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.

HTA Expert Warns Of Escalating Measures If Pharma Fails To Tame Prices

 
• By Francesca Bruce

Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.